AI Article Synopsis

  • Sleep problems in infants treated with propranolol for hemangiomas may indicate potential central nervous system effects; however, this study objectively compares the sleep behavior of treated infants with healthy controls.
  • The study involved 54 infants in both groups monitored for sleep using actigraphy and diaries over 7-10 days at 3 and 6 months; findings at 6 months showed treated infants had decreased sleep efficiency and more nighttime awakenings.
  • Despite these changes, 24-hour total sleep remained stable, and no negative impact on subjective sleep quality or behavioral development was observed, supporting the use of propranolol as a first-line treatment for infantile hemangiomas.

Article Abstract

Sleep problems are frequently reported in infants treated with propranolol for infantile hemangiomas, possibly serving as a marker for a negative impact on central nervous system function. In this cohort study, we objectively investigate the sleep behavior of infants with infantile hemangiomas on propranolol compared to a healthy, untreated control group. Sleep of propranolol-treated infants and controls was investigated using ankle actigraphy and a 24-h diary for 7-10 days at ages 3 and 6 months. The main outcome measures were the Number of Nighttime Awakenings and Sleep Efficiency. The main secondary outcome measures included 24-hour Total Sleep, daytime sleep behavior, and parent-rated infant sleep quality and behavioral development based on the Brief Infant Sleep Questionnaire (BISQ) and the age-appropriate Ages-and-Stages Questionnaire (ASQ), respectively. Fifty-four term-born infants were included in each cohort. No group difference in any investigated parameter was seen at age 3 months. At age 6 months, the propranolol group exhibited a decrease in Sleep Efficiency and a trend towards an increased Number of Nighttime Awakenings compared to the control group. Treated infants at 6 months also had shorter daytime waking periods. 24-hour Total Sleep was unaffected by propranolol. No negative impact of propranolol on subjective sleep quality and behavioral development was noted.Conclusion: Propranolol exerts a measurable yet mild impact on objectively assessed infants' sleep measures. Behavioral developmental scores were unaffected. Our results support propranolol as first-line therapy for complicated infantile hemangiomas. What is Known: • Sleep disorders are frequently reported in infants with infantile hemangiomas treated with propranolol and often lead to treatment discontinuation. • Investigations of the sleep pattern in this patient group using objective measures are lacking. What is New: • The sleep pattern of propranolol-treated infants is assessed using actigraphy and a 24-h sleep diary and compared to healthy, untreated controls. • Propranolol leads to a decreased sleep efficiency at night and an increased demand of daytime sleep, yet effects are mild overall.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285307PMC
http://dx.doi.org/10.1007/s00431-021-04147-3DOI Listing

Publication Analysis

Top Keywords

sleep
19
infantile hemangiomas
16
sleep behavior
12
infants infantile
12
sleep efficiency
12
propranolol
9
infants
8
behavior infants
8
cohort study
8
frequently reported
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!